Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.
Since the introduction of combined systemic chemotherapy with 5-folinic-acid (FA) and/or oxaliplatin or irinotecan, the median survival in patients with advanced colorectal cancer has increased to more than 20 months. Novel agents in so-called targeted therapies such as monoclonal antibodies will further increase these excellent survival data in the near future.
Kallinowski
Birgit
B
Praxis for Gastroenterology and Oncology, Scheffelstr. 63, 68723 Schwetzingen, Germany. birgit.kallinowski@web.de
D000284:Administration, Oral; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D002955:Leucovorin / Q000008:administration & dosage; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011355:Prodrugs / Q000008:administration & dosage
D009944:Organoplatinum Compounds; D011355:Prodrugs; D000077150:Oxaliplatin; D000077146:Irinotecan; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin